Gilead Sciences' net income 2006-2023
Gilead Sciences' net income amounted to some 5.7 billion U.S. dollars in 2023, after it had dropped to only 123 million in 2020. The statistic illustrates Gilead Sciences' net income from 2006 to 2023. The company shot to the public spotlight in the first quarter of 2020 for its drug remdesivir (brand name Veklury), which was trialed and later approved against COVID-19.